Most recent update: Thursday, February 14, 2019 - 14:58

Bariatric News - Cookies & privacy policy

- News

Closure of the mesenteric defects using either non-absorbable metal clips or non-absorbable running sutures is a safe and effective measure to reduce the risk for small bowel obstruction after laparoscopic gastric bypass surgery, according to... (more)

14/02/19 - News

A PhD student at Swansea University has begun a study that is exploring patient experiences during their journey through bariatric surgery. Specifically, looking at the patients’ responses to negative emotions prior to surgery and examine whether this information can provide... (more)
14/02/19 - News

GI Dynamics has received Institutional Review Board (IRB) approval to conduct its pivotal trial of EndoBarrier for type 2 diabetes and obesity. The pivotal trial of EndoBarrier, referred to as the 18-1 study, is a randomised (3:1) controlled double-blinded clinical trial... (more)
13/02/19 - News

The results of a Texas A&M University-led study provide insights into the mechanism by which oestrogen can decrease insulin resistance and the production of glucose, reducing incidences of Type 2 diabetes mellitus. Recent research on the prevalence of Type 2 diabetes has... (more)

Meeting preview

13/02/19

On behalf of the executive council of the IFSO Middle East North Africa Chapter (MENAC) it is my honor, privilege and great pleasure...

12/02/19 - News

Novo Nordisk UK has announced that Ozempic (semaglutide), a once-weekly GLP-1 analogue injection1 for the treatment of type 2 diabetes is now available in the UK. According to the company, Ozempic works by mimicking the function of the GLP-1 (human glucagon-like peptide-1)... (more)
08/02/19 - News

A sharp increase in obesity-linked cancers among young adults in the US could foreshadow a reversal in the overall decline in cancer mortality. In a sweeping study covering two-thirds of the US population, researchers from the American Cancer Society, showed that half a dozen... (more)
07/02/19 - News

Three quarters of individuals with type 2 diabetes (T2D) who have Roux-en-Y gastric bypass surgery (RYGB) experienced diabetes remission within one year of treatment, according to researchers from Aarhus University Hospital, Aarhus, Denmark.

More news

07/02/19 - Research
Surgery and T2DM
Three quarters of individuals with type 2 diabetes (T2D) who have Roux-en-Y gastric bypass surgery (RYGB) experienced diabetes remission within one year of treatment, according to researchers from Aarhus University Hospital, Aarhus, Denmark. The study led by Dr Lene R Madsen, Professor Bjørn... (more)
06/02/19 - Research
Excessive weight gain
Excessive weight gain in children under two years can lead to cardiovascular and metabolic risk factors in teenage years including increased cholesterol, being overweight and having fat around the middle, finds new research from the University of Sydney. Obesity and cardiovascular risk factors in... (more)
05/02/19 - Research
Surgery and glucose management
How bariatric surgery helps people with obesity and diabetes is related to changes in the way the gut senses food and nutrients after the operation, according to researchers from the Cambridge University Metabolic Research Laboratories at the Wellcome Trust - MRC Institute of Metabolic Science.... (more)
04/02/19 - Research
Satiety neurons
Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have identified a molecular switch that controls the function of satiety neurons, and therefore, body weight. The worldwide epidemic of obesity has reached record levels, and what was once a problem only... (more)
01/02/19 - Research
Magnetic liver retraction
Levita Magnetic Surgical System facilitates a safe, reproducible, incision-less technique for port-less intra-abdominal liver retraction during bariatric surgery, according to researchers from Duke University Health System in Durham, NC. The study noted that the device successfully permitted... (more)
01/02/19 - Research
Metabolic diseases
Researchers at the Hebrew University of Jerusalem's Institute for Drug Research, Israel, led by Professor Amiram Goldblum, have discovered 27 new molecules that all activate a special protein called PPAR-delta, which have the potential to treat fatty liver disease, obesity, diabetic nephrotoxicity... (more)